Newly Approved Lebrikizumab Shows Promise in Patients With Darker Skin and AD
Andrew F. Alexis, MD, MPH, Professor of Clinical Dermatology at Weill Cornell Medicine in New York, NY, discusses preliminary study results showing that the newly U.S. Food and Drug Administration-approved biologic, lebrikizumab-lbkz (Ebglyss, Lilly), improves post-inflammatory hyperpigmentation secondary to atopic dermatitis (AD) in people with darker skin tones.